OrthADAPT

Phase 2Biologic

HHospital San Carlos, Madrid

OrthADAPT is one of 28 biologic programs targeting Rotator Cuff Tear. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rotator Cuff TearActive, not recruiting

Rotator Cuff TearPhase 2

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Rotator Cuff Tear

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

—2

Naropin

FFresenius Kabi Oncology Ltd.

Approved

—3

Celebrex

PPhiladelphia Eye Associates

Marcaine

IC-Green

CCHX Technologies Inc.

Approved

—6

Decadron

AAspen Global Incorporated

Ultram

Tylenol

Depo-Testosterone

AAzurity Pharmaceuticals

Suboxone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rotator Cuff Tear1 trial

Mensenchymal Stem Cell (MSC) Included in OrthADAPT Membrane for Rotator Cuff Tears Repair

Unknown status·HHospital San Carlos, Madrid·Phase 2·NCT01687777·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OrthADAPT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OrthADAPT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OrthADAPT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital San Carlos, Madrid company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: HHospital San Carlos, Madrid

OrthADAPT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rotator Cuff Tear1 trial

References

Drug Info

Quick Facts

Related News